Palvella Therapeutics, Inc. (PVLA) EBT (2016 - 2022)
Palvella Therapeutics (PVLA) has disclosed EBT for 12 consecutive years, with -$4.0 million as the latest value for Q4 2024.
- On a quarterly basis, EBT fell 128.55% to -$4.0 million in Q4 2024 year-over-year; TTM through Dec 2024 was -$17.4 million, a 74.03% decrease, with the full-year FY2024 number at -$17.4 million, down 193.27% from a year prior.
- EBT was -$4.0 million for Q4 2024 at Palvella Therapeutics, up from -$6.8 million in the prior quarter.
- In the past five years, EBT ranged from a high of $13.8 million in Q4 2023 to a low of -$19.0 million in Q3 2021.
- A 5-year average of -$7.8 million and a median of -$9.2 million in 2021 define the central range for EBT.
- Peak YoY movement for EBT: tumbled 1508.69% in 2020, then surged 223.93% in 2023.
- Palvella Therapeutics' EBT stood at -$12.4 million in 2020, then increased by 11.27% to -$11.0 million in 2021, then dropped by 1.48% to -$11.2 million in 2022, then soared by 223.93% to $13.8 million in 2023, then tumbled by 128.55% to -$4.0 million in 2024.
- Per Business Quant, the three most recent readings for PVLA's EBT are -$4.0 million (Q4 2024), -$6.8 million (Q3 2024), and -$4.2 million (Q2 2024).